Drug intelligence / Profile preview

BCL6-760

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

BCL6-760: sourced facts only. name: "The discovery of a potent and selective BCL6 ligand-directed degrader (LDD), BCL6-760 (45) is described." [PMID:41055242]; target: "The discovery of a potent and selective BCL6 ligand-directed degrader (LDD), BCL6-760 (45) is described." [PMID:41055242]; developer: "Bristol Myers Squibb, 10300 Campus Point Dr. Suite 100, San Diego, California 92121, United States." [PMID:41055242]; modality: "The discovery of a potent and selective BCL6 ligand-directed degrader (LDD), BCL6-760 (45) is described." [PMID:41055242]; stage: "At 60 mg/kg BID dosing, BCL6-760 achieves >90% BCL6 reduction and leads to an overall 64% tumor volume reduction in an OCI-LY-1 mouse xenograft efficacy model." [PMID:41055242]

Targets

BCL6 (B cell lymphoma 6 protein)

Beyond the preview

Go deeper on BCL6-760.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL6-760.